event-icon
Description

Immunotherapies represent the next generation of cancer therapeutics and have shown dramatic impact and durable responses on a wide variety of tumor types. However, these therapies only provider durable outcomes for 20-40% of patients and up to 90% of patients are expected to experience a so-called immune related adverse event. Large scale EHR data from multiple institutions, linked to genomic information as well as other environmental data could be used as an underlying architecture to drive the future of precision medicine in cancer immunotherapy research. Participants in this panel discussion will learn more about 1)current lessons learned and challenges faced by those using informatics approaches to understanding cancer immunotherapy outcomes, 2) the availability of data to support precision therapeutics in cancer, 3) the challenges with using EHR data as a source for phenotypic and treatment data linked to genetic data to identify markers for successful treatment as well as risk factors for adverse events.

Learning Objective: Participants in this panel discussion will learn more about 1) current lessons learned and challenges faced by those using informatics approaches to understanding cancer immunotherapy outcomes, 2) the availability of data to support precision therapeutics in cancer, 3) the challenges with using EHR data as a source for phenotypic and treatment data linked to genetic data to identify markers for successful treatment as well as risk factors for adverse events.

Authors:

Theresa Walunas (Presenter)
Northwestern University

Abel Kho (Presenter)
Northwestern University

Nikesh Kotecha (Presenter)
Parker Insititute for Cancer Immunotherapy

Nike Beaubier (Presenter)
Tempus

Presentation Materials:

Tags